Roche vamikibart hits 52-week UME endpoints as FDA weighs BLA
Roche has presented one-year efficacy and safety data from its twin Phase III studies of vamikibart in uveitic macular edema (UME), reporting that the anti-IL-6 monoclonal antibody maintained visual and anatomical improvements through 52 weeks in both trials. The data were disclosed at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans.
In both the MEERKAT and SANDCAT studies, a numerically higher proportion of patients treated with vamikibart achieved a gain of 15 letters or more in best corrected visual acuity compared with sham injection at week 16, the primary endpoint. Key secondary endpoints, including average change from baseline in best corrected visual acuity and central subfield thickness, a measure of macular swelling, were sustained through week 52. Roche also reported a low retreatment burden: around two-thirds of eligible patients required no additional injections after week 16, and most of those who did needed only one top-up dose. The safety profile remained favourable, with low rates of ocular adverse events and intraocular inflammation.
Regulatory path
The FDA has accepted Roche's Biologics License Application (BLA) for vamikibart and is expected to issue an approval decision by July 2027. Regulatory submissions have also been accepted in the European Union, China and Japan, giving Roche a simultaneous multi-market filing position that is relatively unusual for an ophthalmic indication of this size.
If approved, vamikibart would be the first non-steroid targeted therapy specifically indicated for UME, which the company says positions it as a potential new standard of care. Vamikibart carries orphan drug designation in both the United States and the EU, reflecting the condition's rarity relative to other causes of vision loss.
Nisha Acharya, Distinguished Professor of Ophthalmology at UCSF and Director of the Uveitis and Ocular Inflammatory Disease Service, described the unmet need: "Currently, UME is commonly treated with off-label therapies or ocular steroids, the latter carrying significant long-term side effects like glaucoma and cataract formation."
Market context
UME affects a subset of uveitis patients and, while rare in absolute numbers, carries a disproportionate burden. Around 20% of patients progress to sustained blindness within three years of diagnosis, and uveitis overall is estimated to account for 10 to 20% of blindness in the United States and Europe. The condition predominantly affects working-age adults, amplifying its socioeconomic impact.
The competitive landscape for targeted UME therapy is thin precisely because the corticosteroid standard of care, despite its toxicity profile, has been entrenched for decades. Biologics targeting cytokine pathways, including TNF inhibitors and IL-6 inhibitors, have been used off-label in non-infectious uveitis, but no agent has previously reached approval in a randomised, sham-controlled Phase III programme in this specific indication. That gives Roche first-mover regulatory advantage in a niche where the price of orphan-designated biologics can support premium positioning.
Roche has described ophthalmology as a strategic priority, with a pipeline spanning retinal vascular disease, geographic atrophy, diabetic eye disease and autoimmune conditions. Vamikibart fits within a broader push to extend anti-cytokine biology, already well-established in rheumatology and oncology, into ocular indications where the intravitreal route allows targeted delivery at low systemic doses. Investors will be tracking the PDUFA window and whether Roche can translate the orphan designation into an accelerated post-approval commercial ramp, particularly in markets such as the EU and Japan where regulatory review is running in parallel.